Participant flow

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma · Source last updated 2026-06-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received intravenous (IV) infusion of 2.5 milligram (mg)/kilogram (kg) belantamab mafodotin on Day 1 of Cycle 1 and 1.9 mg/kg on Day 1 of Cycle 2 onwards in each 28-day cycle, in combination with oral 4 mg per day Pomalidomide capsule on Days 1 to 21 of each 28-day cycle; and oral 40 mg per day Dexamethasone tablet on Days 1, 8, 15, and 22 of each 28-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, initiation of another anti-myeloma therapy or end of study, whichever occurs first.

   id

   FG000

   title

   Belantamab Mafodotin+Pomalidomide+Dexamethasone

2. description

   Participants with RRMM received oral 4 mg per day Pomalidomide capsule on Days 1 to 14 of each 21-day cycle, in combination with subcutaneous (SC) injection of 1.3 mg/meter\^2(m\^2) Bortezomib on Days 1, 4, 8, 11, of each 21-day cycle for Cycles 1 through 8, and on Days 1, 8, of each 21-day cycle for Cycles 9+, and oral 20 mg Dexamethasone tablet on Days 1, 2, 4, 5, 8, 9, 11, 12, of each 21-day cycle for Cycles 1 through 8 and then on Days 1, 2, 8, 9, every 3 Weeks (Q3W) from Cycles 9 onwards until disease progression, death, unacceptable toxicity, withdrawal of consent, initiation of another anti-myeloma therapy or end of study, whichever occurs first.

   id

   FG001

   title

   Pomalidomide+Bortezomib+Dexamethasone

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         1

      type

      Lost to Follow-up

   2. reasons

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         0

      type

      Protocol Deviation

   3. reasons

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         0

      type

      Physician Decision

   4. reasons

      1. group Id

         FG000

         num Subjects

         11

      2. group Id

         FG001

         num Subjects

         8

      type

      Withdrawal by Subject

   5. reasons

      1. group Id

         FG000

         num Subjects

         94

      2. group Id

         FG001

         num Subjects

         84

      type

      Ongoing

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         155

      2. group Id

         FG001

         num Subjects

         147

      comment

      Intent-to-Treat (ITT) Population included of all randomized participants whether or not randomized treatment was administered.

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         150

      2. group Id

         FG001

         num Subjects

         145

      comment

      All randomized participants who received at least 1 dose of study intervention (any component).

      type

      Safety Population

   3. achievements

      1. comment

         Note: Participants who died following randomization whilst on study, including 1 participant who died prior to dosing.

         group Id

         FG000

         num Subjects

         48

      2. comment

         Note: Participants who died following randomization whilst on study, including 1 participant who died prior to dosing.

         group Id

         FG001

         num Subjects

         54

      comment

      Note: Participants who died following randomization whilst on study, were considered to have completed the study.

      type

      COMPLETED

   4. achievements

      1. group Id

         FG000

         num Subjects

         107

      2. group Id

         FG001

         num Subjects

         93

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

The results presented are until the primary completion date. Additional results will be provided within a year of study completion.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice